|
1) National Cholesterol Education Program: Report of the National Cholesterol Education Program expert panel on detection, evaluation, and treatment of high blood cholesterol in adults: the Expert Panel. Arch Intern Med. 1988; 148: 36-69
|
|
|
|
2) National Cholesterol Education Program: Second report of the expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel II). Circulation. 1994; 89: 1333-445
|
|
|
|
|
|
3) Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001; 285: 2486-97
|
|
|
|
|
|
4) Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004; 110: 227-39
|
|
|
|
|
|
5) 日本動脈硬化学会高脂血症診療ガイドライン検討委員会. 高脂血症治療ガイドライン. 動脈硬化. 1997; 25: 1-34
|
|
|
|
|
6) Matsuzaki M, Kita T, Mabuchi H, et al; The J-LIT Study Group. Large scale cohort study of the relationship between serum cholesterol concentration and coronary events with low-dose simvastatin therapy in Japanese patients with hypercholesterolemia. Circ J. 2002; 66: 1087-95
|
|
|
|
|
7) Pravastatin use and risk of coronary events and cerebral infarction in japanese men with moderate hypercholesterolemia: the Kyushu Lipid Intervention Study. J Atheroscler Thromb. 2000; 7: 110-21
|
|
|
|
|
|
8) Ito H, Ohashi Y, Saito Y, et al. A comparison of low versus standard dose pravastatin therapy for the prevention of cardiovascular events in the elderly: the pravastatin anti-atherosclerosis trial in the elderly. J Atheroscler Thromb. 2001; 8: 33-44
|
|
|
|
|
|
9) 日本動脈硬化学会, 編. 動脈硬化性疾患診療ガイドライン2002年版. 東京: エムディエス; 2002
|
|
|
|
|
|
10) 日本動脈硬化学会, 編. 動脈硬化性疾患予防ガイドライン2007年版. 東京: 協和企画; 2007
|
|
|
|
|
|
11) Okamura T, Tanaka H, Miyamatsu N, et al; for the NIPPON DATA80 research group. The relationship between serum total cholesterol and all-cause or cause-specific mortality in a 17. 3- year study of a Japanese cohort. Atherosclerosis. 2007; 190: 216-23
|
|
|
|
|
|
12) Nakamura H, Arakawa K, Itakura H, et al; Primary prevention of cardiovasculara disease in Japan. Results of the Management of Elevated Cholesterol in the Primary Prevention. Group of Adult Japanese (MEGA), Randomized Study with Pravastatin. Lancet. 2006; 368: 1155-63
|
|
|
|
|
|
13) Yokoyama M, Origasa H, Matsuzaki M, et al. Effects of Eicosapentaenoic acid (EPA) on Major Coronary Events in Hypercholesterolemic patients: The Japan EPA Lipid Intervention Study (JELIS). Lancet. 2007; 369: 1090-8
|
|
|
|
|
|
14) 山口武典. 我が国の脳卒中診療の現状と21世紀の展望. 脳卒中. 2001; 23: 261-8
|
|
|
|
|
|
15) 藤島正敏. 日本人の脳血管障害. 日本内科学会雑誌. 1996; 85: 39-50
|
|
|
|
|
|
16) Colhoun HM, Betteridge DJ, Durrington PN, et al; CARDS investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomized placebo-controlled trial. Lancet. 2004; 364: 685-96
|
|
|
|
|
|
17) Sever PS, Dahlof B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet. 2003; 361: 1149-58
|
|
|
|
|
|
18) Oikawa S, Kita T, Mabuchi H, et al; J-LIT Study Group. Risk of coronary events in Japanese patients with both hypercholesterolemia and type 2 diabetes mellitus on low-dose simvastatin therapy: implication from Japan Lipid Intervention Trial (J-LIT). Atherosclerosis. 2007; 191: 440 -6
|
|
|
|
|
|
19) Gaede P, Vedel P, Larsen N, et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 2003; 348: 383-93
|
|
|
|
|
|
20) Ueshima H, Choudhury SR, Okayama A, et al. Cigarette smoking as a risk factor for stroke death in Japan: NIPPON DATA80. Stroke. 2004; 35: 1836-41
|
|
|
|
|
|
21) Iso H, Date C, Yamamoto A, et al; JACC Study Group. Smoking cessation and mortality from cardiovascular disease among Japanese men and women: the JACC Study. Am J Epidemiol. 2005; 161: 170-9
|
|
|
|
|
|
22) メタボリックシンドローム診断基準検討委員会. メタボリックシンドロームの定義と診断基準. 日本内科学会誌. 2005; 94: 188-203
|
|
|
|
|
|
23) Sakamoto T, Kojima S, Ogawa H, et al; Multicenter Study for Aggressive Lipid-Lowering Strategy by HMG-CoA Reductase Inhibitors in Patients With Acute Myocardial Infarction Investigators. Effects of early statin treatment on symptomatic heart failure and ischemic events after acute myocardial infarction in Japanese. Am J Cardiol. 2006; 97: 1165-71
|
|
|
|
|
|
24) Okazaki S, Yokoyama T, Miyauchi K, et al. Early statin treatment in patients with acute coronary syndrome: demonstration of the beneficial effect on atherosclerotic lesions by serial volumetric intravascular ultrasound analysis during half a year after coronary event: the ESTABLISH Study. Circulation. 2004; 110: 1061-8
|
|
|
|
|